Laos Pharma No.2 Molnupiravir 200mg

Product Information

• Product name: Molnupiravir 200mg
• Manufacturer / brand: Laos State Pharmaceutical No.2
• Active ingredient: Molnupiravir
• Current strength: 200mg
• SKU: L2-ITEM-40
• Site category: general medicines

Product Summary

Molnupiravir 200mg is an AISTIKA-listed product supplied by Laos State Pharmaceutical No.2. This page summarizes the product identity, strength, SKU, site category, and public medical reference information. Product name, manufacturer, packaging, and strength follow this AISTIKA product page.

Active Ingredient and Reference Data

Molnupiravir is the active ingredient used for this product page. Public prescribing information for Molnupiravir was used for the medical reference sections. Medical details are provided for reference and must be interpreted by a qualified healthcare professional.

Mechanism of Action

Molnupiravir is a prodrug with antiviral activity against SARS-CoV-2. It is metabolized to the cytidine nucleoside analogue, NHC which distributes into cells where NHC is phosphorylated to form the pharmacologically active ribonucleoside triphosphate (NHC-TP). NHC-TP incorporation (as NHC-monophosphate [NHC-MP]) into SARS-CoV-2 RNA by the viral RNA polymerase (nsp12) results in an accumulation of errors in the viral genome leading to inhibition of replication.

Reference Indications

Reference indications could not be safely generated from an automatically matched public label. Indication, eligibility, and treatment setting must be confirmed by a physician using the current approved label and the patient’s clinical context.

Reference Dosage and Administration

The public label should be checked for the indication-specific recommended dosage. Available administration instructions note that the medicine may be taken taken orally every 12 hours for 5 days, with or without food .

Dose conversion must be confirmed by a physician because the reference dose may vary by indication, organ function, toxicity, or interacting medicines.

This reference dosage is not an individualized prescription. Dose changes, treatment interruptions, or discontinuation must be directed by a physician.

Important Safety Information

MANDATORY REQUIREMENTS FOR ADMINISTRATION OF Molnupiravir UNDER EMERGENCY USE AUTHORIZATION In order to mitigate the risks of using this unapproved product under the EUA and to optimize the potential benefit of Molnupiravir, the following steps are required. Use of Molnupiravir under this EUA is limited to the following (all requirements must be met): Treatment of adults with mild-to-moderate COVID-19 who are at high risk for progression to severe COVID-19, including hospitalization or death and for whom alternative COVID-19 treatment options approved or authorized by FDA are not accessible or clinically appropriate . As the prescribing healthcare provider, review the information contained within the “Fact Sheet for Patients and Caregivers” with your patient or caregiver prior to the patient receiving Molnupiravir.

Common Adverse Reactions and Monitoring

The adverse reaction rates observed in these clinical trials cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Additional adverse events associated with Molnupiravir may become apparent with more widespread use. Overall, more than 900 subjects have been exposed to Molnupiravir 800 mg twice daily in clinical trials. The safety assessment of Molnupiravir is primarily based on an analysis from subjects followed through Day 29 in the Phase 3 study in non-hospitalized subjects with COVID-19 (MOVe-OUT) .

Drug Interactions and Special Populations

No clinical drug-drug interaction trials of Molnupiravir with concomitant medications, including other treatments for mild-to-moderate COVID-19, have been conducted . The prescribing healthcare provider must document that a pregnant individual was made aware of the pregnancy registry at https://covid-pr.pregistry.com or 1-800-616-3791. Pregnant individuals exposed to Molnupiravir or their healthcare providers can also report the exposure by contacting Merck Sharp & Dohme LLC, Rahway, NJ USA at 1-877-888-4231. Risk Summary Based on animal data, Molnupiravir may cause fetal harm when administered to pregnant individuals.

Storage and Purchase Notes

Store according to the package or pharmacist instructions and keep out of reach of children. Before ordering, confirm product name, strength, quantity, price, shipping details, and payment method. After receipt, check packaging, batch number, expiration date, and storage conditions.

Sources

Sources: LAGEVRIO public prescribing information; openFDA/DailyMed public label data. These sources are used for public medical reference. Product information follows this AISTIKA product page.

DisclaimerThis page is for product information and public-label reference only. It does not provide diagnosis, prescription, or individualized medical advice. Consult a physician for treatment decisions.